Literature DB >> 16548884

The human cytomegalovirus glycoprotein UL16 traffics through the plasma membrane and the nuclear envelope.

Mar Valés-Gómez1, Adam Winterhalter, Pedro Roda-Navarro, Albert Zimmermann, Louise Boyle, Hartmut Hengel, Andrew Brooks, Hugh T Reyburn.   

Abstract

The human cytomegalovirus (HCMV) UL16 gene encodes a glycoprotein that interferes with the immune response to the virus-infected cell. In vitro, UL16 interacts with MICB and ULBPs that are ligands for the stimulatory receptor NKG2D, expressed on NK cells and CD8(+)T cells. UL16 expression has been shown to promote intracellular accumulation of MICB, ULBP1 and 2 and thus, interfere with the immune response to HCMV-infected cells. The mechanism that has been suggested for UL16-mediated MICB downmodulation is retention in the ER. Here, we studied the intracellular localization and maturation of UL16 and MICB in HCMV-infected cells and transfectant systems. UL16 trafficked through the ER, TGN and progressed to the plasma membrane, after which the protein was internalized. Strikingly, UL16 was also observed in the inner nuclear membrane. MICB was also localized in the TGN in HCMV-infected cells. These data suggest that MICB trafficking might be affected after its transit through the ER.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16548884     DOI: 10.1111/j.1462-5822.2005.00645.x

Source DB:  PubMed          Journal:  Cell Microbiol        ISSN: 1462-5814            Impact factor:   3.715


  11 in total

1.  A short half-life of ULBP1 at the cell surface due to internalization and proteosomal degradation.

Authors:  Lola Fernández-Messina; Hugh T Reyburn; Mar Valés-Gómez
Journal:  Immunol Cell Biol       Date:  2016-01-06       Impact factor: 5.126

2.  Transfer of the human NKG2D ligands UL16 binding proteins (ULBP) 1-3 is related to lytic granule release and leads to ligand retransfer and killing of ULBP-recipient natural killer cells.

Authors:  Sheila López-Cobo; Gema Romera-Cárdenas; Eva M García-Cuesta; Hugh T Reyburn; Mar Valés-Gómez
Journal:  Immunology       Date:  2015-06-25       Impact factor: 7.397

3.  Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitors.

Authors:  Sheila López-Cobo; Natalia Pieper; Carmen Campos-Silva; Eva M García-Cuesta; Hugh T Reyburn; Annette Paschen; Mar Valés-Gómez
Journal:  Oncoimmunology       Date:  2017-11-06       Impact factor: 8.110

Review 4.  Origins of natural killer cell memory: special creation or adaptive evolution.

Authors:  Kayla A Holder; Emilie M Comeau; Michael D Grant
Journal:  Immunology       Date:  2018-02-15       Impact factor: 7.397

5.  Innate immune recognition of double-stranded RNA triggers increased expression of NKG2D ligands after virus infection.

Authors:  Gloria Esteso; Susana Guerra; Mar Valés-Gómez; Hugh T Reyburn
Journal:  J Biol Chem       Date:  2017-10-06       Impact factor: 5.157

6.  Human NKG2D-ligands: cell biology strategies to ensure immune recognition.

Authors:  Lola Fernández-Messina; Hugh T Reyburn; Mar Valés-Gómez
Journal:  Front Immunol       Date:  2012-09-25       Impact factor: 7.561

7.  The human herpesvirus-7 (HHV-7) U21 immunoevasin subverts NK-mediated cytoxicity through modulation of MICA and MICB.

Authors:  Christine L Schneider; Amy W Hudson
Journal:  PLoS Pathog       Date:  2011-11-10       Impact factor: 6.823

8.  Feeling manipulated: cytomegalovirus immune manipulation.

Authors:  Mindy Miller-Kittrell; Tim E Sparer
Journal:  Virol J       Date:  2009-01-09       Impact factor: 4.099

9.  Natural-killer cell ligands at the maternal-fetal interface: UL-16 binding proteins, MHC class-I chain related molecules, HLA-F and CD48.

Authors:  Richard Apps; Lucy Gardner; James Traherne; Victoria Male; Ashley Moffett
Journal:  Hum Reprod       Date:  2008-07-24       Impact factor: 6.918

10.  Immunoassays for scarce tumour-antigens in exosomes: detection of the human NKG2D-Ligand, MICA, in tetraspanin-containing nanovesicles from melanoma.

Authors:  Sheila López-Cobo; Carmen Campos-Silva; Amanda Moyano; Myriam Oliveira-Rodríguez; Annette Paschen; María Yáñez-Mó; María Carmen Blanco-López; Mar Valés-Gómez
Journal:  J Nanobiotechnology       Date:  2018-05-02       Impact factor: 10.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.